Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

ABSTRACT:

Importance

Evidence of effective smoking cessation interventions in patients with diabetes is limited. The unique behavioral and metabolic characteristics of smokers with type 2 diabetes warrants a randomized clinical trial of the smoking cessation drug varenicline.

Objective

To evaluate the efficacy and safety of varenicline in patients with type 2 diabetes with an intention to quit smoking.

Design, setting, and participants

This multicenter, double-blind, placebo-controlled randomized clinical trial recruited patients from 6 outpatient clinics in 5 hospitals in Catania, Italy. Patients with type 2 diabetes, who were smoking at least 10 cigarettes a day, and who intended to quit smoking were screened for eligibility. Eligible patients were randomized to either vareni

SUBMITTER: Russo C 

PROVIDER: S-EPMC9214580 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature